Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages 1-9

  Huang, Liang ^a,b   Chen, Tianwen ^c   Chen, Canming ^a,b   Chen, Sheng ^a,b   Liu, Yin ^a,b   Wu, Jiong ^a,b   Shao, Zhiming ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; HER2 neu; Neoadjuvant chemotherapy; Overall survival; pAKT; Phospho p44 42; Prognostic factors; Relapse free survival

Indexed keywords

ANTHRACYCLINE; CYCLIN D1; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27; PROTEIN P42; PROTEIN P44; RAS PROTEIN; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ERBB2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TUMOR MARKER; VINBLASTINE;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; ADJUVANT THERAPY; AGED; BREAST TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 84890118466     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-307     Document Type: Article

References (30)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
2. De Placido S, Perrone F, Carlomagno C, Morabito A, Pagliarulo C, Lauria R, Marinelli A, De Laurentiis M, Varriale E, Petrella G, Gallo C, Bianco AR. CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). Br J Cancer 1995, 71:1283-1287. 10.1038/bjc.1995.248, 2033842, 7779724.
3. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006, 354:2103-2111. 10.1056/NEJMoa054504, 16707747.
4. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL. Wolmark N: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998, 90:1361-1370. 10.1093/jnci/90.18.1361, 9747867.
5. Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 2008, 109:209-229. 10.1007/s10549-007-9656-y, 17636396.
6. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008, 100:14-20. 10.1093/jnci/djm252, 18159072.
7. Montemurro F, Aglietta M. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Clin Breast Cancer 2005, 6:77-80. 10.3816/CBC.2005.n.011, 15899075.
8. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012, 30:1796-1804. 10.1200/JCO.2011.38.8595, 22508812.
9. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T,. Nekljudova V, von Minckwitz G, German Breast Group (GBG), Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study group Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012, 13:135-144. 10.1016/S1470-2045(11)70397-7, 22257523, Nekljudova V, von Minckwitz G, German Breast Group (GBG), Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study group.
10. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008, 26:4078-4085. 10.1200/JCO.2007.13.4429, 2654368, 18757322.
11. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R, Glazer PM. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997, 57:3079-3083.
12. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF,. American Society of Clinical Oncology/College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145. American Society of Clinical Oncology/College of American Pathologists.
13. Antonelli M, Massimino M, Morra I, Garre ML, Gardiman MP, Buttarelli FR, Arcella A, Giangaspero F. Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL40 and prognostic significance. Neuropathology 2012, 32:133-138. 10.1111/j.1440-1789.2011.01252.x, 21978279.
14. Chen S, Chen CM, Yu KD, Yang WT, Shao ZM. A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer. J Surg Oncol 2012, 105:577-585. 10.1002/jso.22140, 22065549.
15. Taunk NK, Goyal S, Moran MS, Yang Q, Parikh R, Haffty BG. Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiother Oncol 2010, 96:204-208. 10.1016/j.radonc.2010.03.009, 20338651.
16. Sangale Z, Prass C, Carlson A, Tikishvili E, Degrado J, Lanchbury J, Stone S. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol 2011, 19:173-183. 10.1097/PAI.0b013e3181f1da13, 20930614.
17. Von Minckwitz G, Loibl S, Untch M. What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?. Oncology 2012, 26:20-26.
18. Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol 2009, 20:648-654. 10.1093/annonc/mdn681, 19188134.
19. Andre F, Nahta R, Conforti R, Boulet T, Aziz M, Yuan LX, Meslin F, Spielmann M, Tomasic G, Pusztai L, Hortobagyi GN, Michiels S, Delaloge S, Esteva FJ. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol 2008, 19:315-320. 10.1093/annonc/mdm429, 17804473.
20. Gallardo A, Lerma E, Escuin D, Tibau A, Muñoz J, Ojeda B, Barnadas A, Adrover E, Sánchez-Tejada L, Giner D, Ortiz-Martínez F, Peiró G. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 2012, 106:1367-1373. 10.1038/bjc.2012.85, 3326683, 22454081.
21. Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Cancer Invest 2008, 26:671-679. 10.1080/07357900801891628, 18608215.
22. Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res 2008, 10:R27. 10.1186/bcr1984, 2397526, 18371219.
23. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091. 10.1158/0008-5472.CAN-07-6854, 2680495, 18676830.
24. Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 2008, 13:259-271. 10.1007/s10495-007-0165-6, 18071906.
25. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, Murphy LC. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 2002, 8:1747-1753.
26. Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortobagyi GN. High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist 2012, 17:766-774. 10.1634/theoncologist.2011-0377, 3380875, 22584435.
27. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006, 46:249-279. 10.1016/j.advenzreg.2006.01.004, 16854453.
28. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009, 116:53-68. 10.1007/s10549-008-0081-7, 18592370.
29. Tanei T, Shimomura A, Shimazu K, Nakayama T, Kim SJ, Iwamoto T, Tamaki Y, Noguchi S. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 2011, 37:155-161. 10.1016/j.ejso.2010.10.009, 21111561.
30. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M, Kahmann L, Lux MP, Strehl JD, Hartmann A, Dimmler A, Beckmann MW, Wachter DL. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011, 11:486. 10.1186/1471-2407-11-486, 3262864, 22081974.